GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Predilife SA (XPAR:ALPRE) » Definitions » Loans Receivable

Predilife (XPAR:ALPRE) Loans Receivable : €0.00 Mil (As of Jun. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Predilife Loans Receivable?

Predilife's Loans Receivable for the quarter that ended in Jun. 2023 was €0.00 Mil.


Predilife Loans Receivable Historical Data

The historical data trend for Predilife's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predilife Loans Receivable Chart

Predilife Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Loans Receivable
Get a 7-Day Free Trial - - - - -

Predilife Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Predilife Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Predilife Loans Receivable Related Terms

Thank you for viewing the detailed overview of Predilife's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Predilife (XPAR:ALPRE) Business Description

Traded in Other Exchanges
N/A
Address
114 rue Edouard Vaillant Espace Maurice Tubiana, Villejuif, Paris, FRA, 94800
Predilife SA develops solutions of predictive medicine combining proven medical techniques (genetic tests, medical imaging) and mathematical models using a large number of statistical data that could allow each individual to define his risk profile for the occurrence of a large number of serious diseases. The company markets its Mammorisk personalized breast cancer screening solution in Europe and the United States.

Predilife (XPAR:ALPRE) Headlines

No Headlines